---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-22-000102"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:38:55.995663+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Instil Bio discontinues ITIL-168, cuts 60% of U.S. workforce, COO departs

## Summary
- Discontinuing ITIL-168 (unmodified TIL) programs; prioritizing CoStAR-TIL platform (ITIL-306) in Phase 1 for NSCLC, ovarian, RCC.
- U.S. workforce reduced by ~60%; restructuring expected substantially complete in February 2023.
- Estimated aggregate restructuring costs up to $20 million; COO Timothy Moore departing Dec 8, 2022, consulting 3 months.
- Initial ITIL-306 Phase 1 data expected in 2023; first patient dosed in 2022.

## SEC filing metadata
- accession: 0001789769-22-000102
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976922000102/0001789769-22-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976922000102/til-20221202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-22-000102
- JSON: https://secwatch.observer/filing/0001789769-22-000102.json
- Plain text: https://secwatch.observer/filing/0001789769-22-000102.txt

## Key facts
- Executive change
  Timothy Moore departed as Chief Operating Officer at Instil Bio, Inc..
  - Action: will separate
  - Role: Chief Operating Officer
  source text: Timothy Moore, the Company’s Chief Operating Officer, will separate from the Company, effective December 8, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976922000102/0001789769-22-000102-index.htm
- Restructurings & Charges
  Instil Bio, Inc. announced a restructuring with charges of up to $20 million affecting ITIL-168 development program and U.S. workforce (approximately 60%).
  - Type: restructuring
  - Charge: up to $20 million
  - Affected area: ITIL-168 development program and U.S. workforce
  - Headcount: approximately 60%
  source text: As part of the Plan, the Company’s ITIL-168 development program will be discontinued. In addition, as part of the Plan, the Company will reduce its US workforce by approximately 60%. This workforce reduction is expected to be substantially completed in February 2023. In connection with the Plan, the Company estimates that it will incur aggregate restructuring costs of up to $20 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976922000102/0001789769-22-000102-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.